Search

技术交流座谈会助推生物制药工业全速发展

      6月4日，由北京经济技术开发区海外学人中心与安泰吉（北京）生物技术有限公司共同主办的“生物医药专题技术交流和推广座谈会”在博大大厦举办。这是一场由多家新区生物制药企业的技术专家和高管参与的高端生物医药技术交流座谈会，旨在促进开发区的生物医药企业之间的技术交流和合作，整体提升开发区的生物医药产业水平。

      会上，安泰吉（北京）生物技术有限公司董事长高闻达博士，以 “重组蛋白质哺乳动物细胞表达系统技术平台的创立和对外服务”为报告专题，向参会的技术专家和企业高管介绍了公司的该项核心技术，并与参会专家展开了热烈的技术讨论。

安泰吉公司获得北京市科学技术委员会的科技服务业促进专项的支持

http://www.antagenbeijing.com/sites/default/files/news/company-news-4.jpg      安泰吉公司创立的自主知识产权的 “重组蛋白质哺乳动物细胞高效表达系统技术”，获得了北京市科委的 “科技服务业促进专项” 的立项批准和资助。

      该“医用重组蛋白质哺乳动物细胞高效表达系统”具有快稳高三大技术优势。一旦完成此高效表达系统技术的落地和工艺优化，安泰吉将对加快成果产业化部署，使得该技术的经济效益和社会效益尽快显现。（文/张士琴）

 

 

Stable Production of Antibodies

Stable Production of Antibodies

 
Wild type Antibodies
Compared with monoclonal antibodies derived from polyclonal antibodies and hybridoma, the recombinant antibody has the following advantages: 1) the antibody recognizes single epitope and has repeatability and specificity; 2) the influence of the instability of the hybrid tumor on the expression of the antibody was solved. 3) It can be modified on the sequence of antibodies to meet various needs; 4) mass production; 5) it is easier to control the differences between batches.

Stable Production of Antibodies

Stable Production of Antibodies

 
Wild type Antibodies
Compared with monoclonal antibodies derived from polyclonal antibodies and hybridoma, the recombinant antibody has the following advantages: 1) the antibody recognizes single epitope and has repeatability and specificity; 2) the influence of the instability of the hybrid tumor on the expression of the antibody was solved. 3) It can be modified on the sequence of antibodies to meet various needs; 4) mass production; 5) it is easier to control the differences between batches.